Amica Pension Fund Board Of Trustees Has Trimmed Union Pacific (UNP) Holding; Abbott Laboratories (ABT) Covered By 17 Bullish Analysts Last Week

January 22, 2018 - By Darrin Black

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 17 have Buy rating, 0 Sell and 8 Hold. Therefore 68% are positive. Abbott Laboratories had 93 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Tuesday, June 14 by Jefferies. The company was maintained on Thursday, October 19 by Citigroup. The rating was maintained by Deutsche Bank on Friday, July 21 with “Buy”. The stock has “Hold” rating by Northland Capital on Thursday, September 28. As per Thursday, April 20, the company rating was maintained by Barclays Capital. The firm earned “Buy” rating on Monday, June 26 by RBC Capital Markets. Barclays Capital maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, October 19. Barclays Capital has “Overweight” rating and $64 target. The firm has “Neutral” rating by Goldman Sachs given on Friday, November 13. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Friday, October 9. RBC Capital Markets has “Outperform” rating and $51 target. The rating was maintained by Jefferies on Tuesday, September 13 with “Buy”. See Abbott Laboratories (NYSE:ABT) latest ratings:

22/01/2018 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Downgrade
02/01/2018 Broker: Guggenheim Rating: Buy New Target: $68.0 Maintain
03/01/2018 Broker: Evercore Rating: Outperform New Target: $64 Initiates Coverage On
02/01/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
02/01/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade
12/12/2017 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Outperform Old Target: $5.00 New Target: $6.00 Upgrade
18/10/2017 Broker: Cowen & Co Rating: Buy New Target: $68.0 Maintain
19/10/2017 Broker: Barclays Capital Rating: Overweight Old Target: $60 New Target: $64 Maintain
19/10/2017 Broker: BMO Capital Markets Rating: Market Perform New Target: $5.00 Maintain
19/10/2017 Broker: Citigroup Rating: Neutral New Target: $5.00 Maintain

Amica Pension Fund Board Of Trustees decreased Union Pacific Corp (UNP) stake by 13.64% reported in 2017Q3 SEC filing. Amica Pension Fund Board Of Trustees sold 4,939 shares as Union Pacific Corp (UNP)’s stock declined 2.52%. The Amica Pension Fund Board Of Trustees holds 31,263 shares with $3.63M value, down from 36,202 last quarter. Union Pacific Corp now has $111.46 billion valuation. The stock increased 0.25% or $0.35 during the last trading session, reaching $141.6. About 1.66 million shares traded. Union Pacific Corporation (NYSE:UNP) has risen 31.45% since January 22, 2017 and is uptrending. It has outperformed by 14.75% the S&P500.

The stock decreased 0.02% or $0.01 during the last trading session, reaching $59.3. About 3.08 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 22, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It dropped, as 47 investors sold Abbott Laboratories shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Invest Counselors Of Maryland Ltd Liability holds 0.05% or 18,235 shares in its portfolio. Beese Fulmer Investment Mgmt Incorporated accumulated 89,458 shares. Washington Tru owns 0.38% invested in Abbott Laboratories (NYSE:ABT) for 119,281 shares. Meyer Handelman owns 100,321 shares. Frontier Invest Management reported 0.04% stake. Walter Keenan Consulting Communications Mi Adv reported 14,766 shares. Mark Sheptoff Financial Planning Ltd Llc stated it has 1.59% of its portfolio in Abbott Laboratories (NYSE:ABT). Northside Capital Management Limited Liability Corporation reported 9,503 shares or 0.21% of all its holdings. Hall Laurie J Trustee invested in 68,526 shares. Hightower Llc stated it has 0.28% of its portfolio in Abbott Laboratories (NYSE:ABT). Stifel Financial Corporation has 0.32% invested in Abbott Laboratories (NYSE:ABT) for 1.72 million shares. Northwest Counselors Limited Liability Com reported 28,041 shares or 0.65% of all its holdings. Steinberg Asset Ltd Company owns 87,357 shares for 1.64% of their portfolio. Fifth Third Bancshares stated it has 0.39% in Abbott Laboratories (NYSE:ABT). Bailard holds 0.05% of its portfolio in Abbott Laboratories (NYSE:ABT) for 12,496 shares.

Since August 1, 2017, it had 0 buys, and 6 selling transactions for $22.86 million activity. $2.74 million worth of Abbott Laboratories (NYSE:ABT) was sold by Contreras Jaime on Friday, September 22. The insider Salvadori Daniel Gesua Sive sold 28,319 shares worth $1.56M. 196,550 Abbott Laboratories (NYSE:ABT) shares with value of $9.73M were sold by Fussell Stephen R. Shares for $98,323 were sold by Bracken Sharon J on Tuesday, August 1.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $103.22 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 47.86 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Among 29 analysts covering Union Pacific Corporation (NYSE:UNP), 13 have Buy rating, 2 Sell and 14 Hold. Therefore 45% are positive. Union Pacific Corporation had 95 analyst reports since July 24, 2015 according to SRatingsIntel. UBS maintained it with “Buy” rating and $107 target in Friday, July 24 report. The company was maintained on Friday, August 25 by Cowen & Co. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, August 18. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, October 31. The firm has “Neutral” rating by UBS given on Friday, October 27. The rating was maintained by RBC Capital Markets with “Hold” on Thursday, September 28. The firm has “Buy” rating by UBS given on Tuesday, March 8. Deutsche Bank maintained Union Pacific Corporation (NYSE:UNP) rating on Friday, January 22. Deutsche Bank has “Buy” rating and $87 target. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, February 23. The firm has “Equal-Weight” rating by Barclays Capital given on Monday, April 11.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: